Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: CAP1

Summary for CAP1

Gene information	Gene symbol	CAP1
	Ensembl ID	ENSG00000131236
	Entrez ID	10487
	Gene name	cyclase associated actin cytoskeleton regulatory protein 1
	Synonyms	CAP
	Gene type	protein_coding
	UniProtAcc	Q01518

Top

Dataset with differentially expressed gene: CAP1

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.289419	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	-0.268888	1.78e-07
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	0.286082	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD4+ T cells	0.252182	3.53e-26
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	0.334368	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.282487	7.33e-43
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.253479	6.94e-04
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.361879	2.41e-20
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.575184	2.64e-19
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	0.378108	8.12e-37
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Mono/Macro	-0.253171	2.44e-11
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.306662	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	B cells	0.824622	3.69e-02
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	0.534927	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	0.484067	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-0.781745	2.26e-02
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-0.372041	2.13e-02
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.498607	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	0.321471	3.30e-14
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.27957	2.22e-09
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.360991	1.61e-23
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.269106	6.72e-09
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.372788	0.00e+00

Top

Expression of CAP1 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to CAP1

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating CAP1

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
CAP1	hsa-miR-448	95.2426	NM_001105530
CAP1	hsa-miR-1260b	94.7632	NM_001105530
CAP1	hsa-miR-1260a	94.7632	NM_001105530
CAP1	hsa-miR-153-3p	92.1842	NM_001105530
CAP1	hsa-miR-205-3p	92.1112	NM_001105530
CAP1	hsa-miR-6508-5p	91.7574	NM_001105530
CAP1	hsa-miR-3123	91.2986	NM_001105530
CAP1	hsa-miR-548b-3p	91.1663	NM_001105530
CAP1	hsa-miR-2355-3p	90.5399	NM_001105530
CAP1	hsa-miR-12135	89.131	NM_001105530
CAP1	hsa-miR-8067	88.2805	NM_001105530
CAP1	hsa-miR-4650-3p	87.8698	NM_001105530
CAP1	hsa-miR-133a-3p	87.441	NM_001105530
CAP1	hsa-miR-133b	87.441	NM_001105530
CAP1	hsa-miR-6859-5p	86.6872	NM_001105530
CAP1	hsa-miR-3916	86.6872	NM_001105530
CAP1	hsa-miR-3125	86.5349	NM_001105530
CAP1	hsa-miR-206	86.3701	NM_001105530
CAP1	hsa-miR-1-3p	86.3701	NM_001105530
CAP1	hsa-miR-202-3p	84.7428	NM_001105530
CAP1	hsa-miR-3976	84.6518	NM_001105530
CAP1	hsa-miR-3664-3p	83.1717	NM_001105530
CAP1	hsa-miR-4496	82.8823	NM_001105530
CAP1	hsa-miR-548m	81.4816	NM_001105530
CAP1	hsa-miR-5000-3p	80.814	NM_001105530
CAP1	hsa-miR-4436a	80.814	NM_001105530
CAP1	hsa-miR-613	80.8018	NM_001105530
CAP1	hsa-miR-4650-5p	80.4514	NM_001105530

Page: 1

Top

Motifs and transcription factors (TFs) regulating CAP1

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
CAP1	transfac_pro__M07387	ZBTB7A (directAnnotation).
CAP1	transfac_pro__M00803	E2F1; E2F3; E2F4; TFDP1 (directAnnotation).
CAP1	transfac_pro__M01783	SP2 (directAnnotation).
CAP1	metacluster_61.1	DEAF1; DEAF1 (directAnnotation).
CAP1	tfdimers__MD00483	ZBTB14 (directAnnotation).
CAP1	transfac_pro__M00915	TFAP2A; TFAP2B; TFAP2C (directAnnotation).
CAP1	hdpi__GTF3C2	GTF3C2 (directAnnotation).
CAP1	metacluster_115.1	NEUROD1; PHF1; ZBTB20; ZNF17; ZNF296; ZNF350; ZNF486; ZNF574; ZNF589; ZNF891 (directAnnotation). IRF4; IRF6; PRDM5 (inferredBy_Orthology).
CAP1	taipale_tf_pairs__TFAP2C_HES7_NNCRCGYGNNNNNNSCCNNNGGS_CAP_repr	HES7; TFAP2C (directAnnotation).
CAP1	transfac_pro__M03806	ZBTB7C (directAnnotation).
CAP1	hdpi__ZNF304	ZNF304 (directAnnotation).
CAP1	metacluster_135.11	NR2C2 (directAnnotation).
CAP1	cisbp__M00788	ZFY (inferredBy_Orthology).
CAP1	transfac_public__M00189	TFAP2A; TFAP2B; TFAP2C (directAnnotation).
CAP1	transfac_pro__M00800	TFAP2A; TFAP2B; TFAP2C (directAnnotation).
CAP1	cisbp__M00343	PAX6 (directAnnotation).
CAP1	transfac_pro__M00430	E2F1 (directAnnotation).
CAP1	metacluster_197.3	E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F1; E2F2; E2F2; E2F2; E2F2; E2F2; E2F3; E2F3; E2F3; E2F3; E2F3; E2F3; E2F3; E2F4; E2F4; E2F4; E2F4; E2F4; E2F4; E2F4; E2F4; E2F4; E2F4; E2F5; E2F5; E2F5; E2F5; E2F6; E2F7; E2F7; E2F7; RB1; TFDP1; TFDP1; TFDP1; TFDP1; TFDP1; TFDP1; TFDP1; TFDP2; TFDP2 (directAnnotation).
CAP1	transfac_pro__M00938	E2F1 (directAnnotation).
CAP1	kznf__ZNF267_Imbeault2017_RP_RCADE	ZNF267 (directAnnotation).
CAP1	transfac_pro__M12694	ZFP14 (directAnnotation).
CAP1	transfac_pro__M04617	ZBTB7A (directAnnotation).
CAP1	metacluster_24.1	HIC1; HIC1; ZNF816; ZNF816; ZNF816; ZXDC (directAnnotation).
CAP1	metacluster_67.2	ZNF501 (directAnnotation). ACAA1; E2F2; E2F2; E2F3; E2F3; FOXN4 (inferredBy_Orthology).
CAP1	transfac_pro__M07437	ZBTB2 (directAnnotation).
CAP1	jaspar__MA0776.1	MYBL1 (directAnnotation).
CAP1	dbtfbs__ZFP91_K562_ENCSR898XMH_merged_N1	ZFP91 (directAnnotation).
CAP1	transfac_pro__M05829	ZNF627 (directAnnotation).
CAP1	metacluster_56.5	HSF1; HSF1; HSF2 (directAnnotation). HSF1; HSF2; HSF4; HSF5; HSFX1; HSFX2; HSFX3; HSFX4; HSFY1; HSFY2 (inferredBy_Orthology).
CAP1	transfac_pro__M06313	ZNF678 (directAnnotation).
CAP1	metacluster_52.11	ZNF184 (directAnnotation).
CAP1	dbtfbs__ZNF423_HEK293_ENCSR477OJI_merged_N1	ZNF423 (directAnnotation).
CAP1	transfac_pro__M12556	ETV4 (directAnnotation).
CAP1	transfac_pro__M05699	ZNF816 (directAnnotation).
CAP1	transfac_pro__M06314	ZNF239 (directAnnotation).
CAP1	tfdimers__MD00364	WT1 (directAnnotation).
CAP1	dbtfbs__E2F8_representative_N1	E2F8 (directAnnotation).
CAP1	kznf__ZNF135_Isakova2017_SMiLE-seq	ZNF135 (directAnnotation).
CAP1	transfac_pro__M06408	ZSCAN30 (directAnnotation).
CAP1	metacluster_178.3	NKX1-1; NKX1-2 (directAnnotation). GSX1; HOXB2; HOXB3 (inferredBy_Orthology).
CAP1	taipale_tf_pairs__RORB_AWNTAGGTCATGACCTANWT_HT	RORB (directAnnotation).
CAP1	jaspar__MA0136.3	ELF5 (inferredBy_Orthology).
CAP1	transfac_pro__M06462	ZNF441 (directAnnotation).
CAP1	jaspar__MA1952.1	FOXJ2 (directAnnotation).

Page: 1 2 3 4

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."